Israel - English - Ministry of Health

padagis israel agencies ltd, israel - tacrolimus as monohydrate - capsules - tacrolimus as monohydrate 5 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients.treatment of allograft rejection resistant to treatment with other immuonosuppressive medicinal products.

Israel - English - Ministry of Health

padagis israel agencies ltd, israel - glyceryl trinitrate - ointment - glyceryl trinitrate 0.4 % - glyceryl trinitrate - glyceryl trinitrate - for relief of pain associated with chronic anal fissure. in the clinical development of the drug a modest effect has shown on improvement in average daily pain intensity.

Israel - English - Ministry of Health

padagis israel agencies ltd, israel - penciclovir - cream - penciclovir 10 mg/g - penciclovir - for the topical treatment for cold sores (oral herpes).

Israel - English - Ministry of Health

padagis israel agencies ltd, israel - penciclovir - cream - penciclovir 10 mg/g - penciclovir - for the topical treatment for cold sores (oral herpes)

Israel - English - Ministry of Health

padagis israel agencies ltd, israel - clotrimazole - cream - clotrimazole 1 %w/w - clotrimazole - for the treatment of fungal infections of the skin and mucosa caused by dermatophytes, yeasts, moulds and other fungi such as malassezia furfur as well as skin infections caused by corynebacterium minutissimum.indicated also for candida vulvitis and candida balanitis.

Israel - English - Ministry of Health

padagis israel pharmaceuticals ltd, israel - clotrimazole; dexamethasone acetate; neomycin sulfate - cream - clotrimazole 1 %; neomycin sulfate 0.645 %; dexamethasone acetate 0.044 % - combinations - combinations - treatment of dermatitis involving also a bacterial and/or fungal infection.

Israel - English - Ministry of Health

padagis israel pharmaceuticals ltd, israel - butenafine hydrochloride - cream - butenafine hydrochloride 1 % - butenafine - butenafine - interdigital tinea pedis, tinea coporis, tinea cruris . (treatment in tinea coporis and tinea cruris is limited to up to 4 weeks).

Israel - English - Ministry of Health

padagis israel agencies ltd, israel - infliximab - powder for concentrate for solution for infusion - infliximab 100 mg/vial - infliximab - * rheumatoid arthritis:remsima, in combination with methotrexate, is indicated for the reduction of signs and symptoms as well as the improvement in physical function in:• adult patients with active disease when the response to disease modifying antirheumatic drugs (dmards),including methotrexate, has been inadequate.• adult patients with severe, active and progressive disease not previously treated with methotrexate or other dmards.in these patient populations, a reduction in the rate of the progression of joint damage, as measured by x ray,has been demonstrated.* ankylosing spondylitis:remsima is indicated for treatment of severe, active ankylosing spondylitis, in adult patients who have responded inadequately to conventional therapy.* psoriatic arthritis:remsima is indicated for treatment of active and progressive psoriatic arthritis in adult patients when the response to previous dmard therapy has been inadequate.* remsima should be administered:• in combination with methotrexate• or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated.infliximab has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by x ray in patients with polyarticular symmetrical subtypes of the disease.* psoriasis:remsima is indicated for treatment of moderate to severe plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen ultra-violet a (puva)* adult crohn’s disease remsima is indicated for treatment :• of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.• treatment of fistulising, active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy).* ulcerative colitis• remsima is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies.paediatric crohn’s diseaseremsima is indicated for treatment of severe, active crohn’s disease in children and adolescents aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for such therapies. infliximab has been studied only in combination with conventional immunosuppressive therapy.paediatric ulcerative colitisremsima is indicated for treatment of severely active ulcerative colitis in children and adolescents aged 6 to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6 mp or aza, or who are intolerant to or have medical contraindications for such therapies.

Israel - English - Ministry of Health

padagis israel agencies ltd, israel - lidocaine; prilocaine - cream - lidocaine 2.5 %; prilocaine 2.5 % - prilocaine, combinations - prilocaine, combinations - topical anaesthetic for superficial dermal analgesia in connection with insertion of iv catheters, blood sampling and superficial surgical procedures.

Israel - English - Ministry of Health

padagis israel agencies ltd, israel - hydroquinone - gel - hydroquinone 4 %w/w - hydroquinone - lightening skin spots.